Work

Supplementary Figure 1 from Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: PDF file, 57K, Baseline levels of Plasma PlGF for the Phase I study with MNRP1658A and Avf0776 were measured using MSD assay. Equivalent levels and similar distribution of PlGF was observed between the two clinical trials.

DOI: 10.1158/1078-0432.22447694.v1

Authors: Yan Xin, Jessica Li, Jenny Wu, Rashell Kinard, Colin D. Weekes, Amita Patnaik, Patricia LoRusso, Rainer Brachmann, Raymond K. Tong, Yibing Yan, Ryan Watts, Shuang Bai, Priti S. Hegde

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361904600

Cites:

Cited by:

Related to: 10